Comparison of a 750 ml spacer and a nebulizer in domiciliary treatment of severe chronic asthma with terbutaline.
Twelve patients with severe chronic obstructive lung disease, participated in this double-blind, cross-over study. Either terbutaline sulphate aerosol or placebo was delivered via a pressurized aerosol with a 750 ml spacer interposed between the actuator and the mouth, or by an electric compressor nebulizer. Each treatment was given for 1 week. The patients recorded PEF and the use of extra terbutaline aerosol while treating themselves at home. All patients completed the treatment periods on terbutaline. Five patients failed to complete the placebo treatment periods because their condition deteriorated. There was no significant difference in bronchodilatation with 5 mg terbutaline using the nebulizer versus 1.5 mg terbutaline using the spacer. We conclude that in the treatment of severe asthma, a pressurized aerosol with a 750 ml spacer can be used either alone, or as a supplement to, treatment with an electric compressor nebulizer.